Wells Fargo’s Cogent Biosciences COGT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.11M | Sell |
106,660
-46,965
| -31% | -$1.73M | ﹤0.01% | 2761 |
|
|
2025
Q4 | $5.46M | Buy |
153,625
+72,621
| +90% | +$2.04M | ﹤0.01% | 2597 |
|
|
2025
Q3 | $1.16M | Buy |
81,004
+25,070
| +45% | +$297K | ﹤0.01% | 3710 |
|
|
2025
Q2 | $402K | Buy |
55,934
+11,306
| +25% | +$62.7K | ﹤0.01% | 4298 |
|
|
2025
Q1 | $267K | Buy |
44,628
+983
| +2% | +$7.71K | ﹤0.01% | 4500 |
|
|
2024
Q4 | $340K | Buy |
43,645
+14,413
| +49% | +$144K | ﹤0.01% | 4442 |
|
|
2024
Q3 | $316K | Sell |
29,232
-912
| -3% | -$8.88K | ﹤0.01% | 4285 |
|
|
2024
Q2 | $254K | Buy |
30,144
+3,291
| +12% | +$25K | ﹤0.01% | 4348 |
|
|
2024
Q1 | $180K | Buy |
26,853
+3,130
| +13% | +$19.3K | ﹤0.01% | 4534 |
|
|
2023
Q4 | $139K | Sell |
23,723
-29,175
| -55% | -$224K | ﹤0.01% | 4699 |
|
|
2023
Q3 | $516K | Sell |
52,898
-9,488
| -15% | -$113K | ﹤0.01% | 3760 |
|
|
2023
Q2 | $739K | Buy |
62,386
+10,616
| +21% | +$122K | ﹤0.01% | 3663 |
|
|
2023
Q1 | $559K | Buy |
+51,770
| New | +$662K | ﹤0.01% | 3763 |
|
|
2022
Q4 | – | Sell |
-1,702
| Closed | -$26K | – | 7499 |
|
|
2022
Q3 | $26K | Buy |
1,702
+1,179
| +225% | +$16.2K | ﹤0.01% | 5265 |
|
|
2022
Q2 | $5K | Sell |
523
-4,419
| -89% | -$30.2K | ﹤0.01% | 5993 |
|
|
2022
Q1 | $37K | Sell |
4,942
-13,059
| -73% | -$90.9K | ﹤0.01% | 5785 |
|
|
2021
Q4 | $154K | Sell |
18,001
-62,680
| -78% | -$545K | ﹤0.01% | 5411 |
|
|
2021
Q3 | $679K | Buy |
80,681
+80,680
| +8,068,000% | +$618K | ﹤0.01% | 4482 |
|
|
2021
Q2 | $0 | Sell |
1
-164
| -99% | -$1.39K | ﹤0.01% | 6949 |
|
|
2021
Q1 | $1K | Sell |
165
-1
| -0.6% | -$10 | ﹤0.01% | 6697 |
|
|
2020
Q4 | $2K | Buy |
166
+133
| +403% | +$1.46K | ﹤0.01% | 6259 |
|
|
2020
Q3 | $0 | Buy |
33
+11
| +50% | +$115 | ﹤0.01% | 6376 |
|
|
2020
Q2 | $0 | Hold |
22
| – | – | ﹤0.01% | 6328 |
|
|
2020
Q1 | $0 | Buy |
+22
| New | +$61 | ﹤0.01% | 6254 |
|
|
2019
Q3 | – | Sell |
-3,484
| Closed | -$37K | – | 6399 |
|
|
2019
Q2 | $37K | Sell |
3,484
-7,812
| -69% | -$104K | ﹤0.01% | 5640 |
|
|
2019
Q1 | $199K | Buy |
11,296
+1,570
| +16% | +$26.8K | ﹤0.01% | 4827 |
|
|
2018
Q4 | $171K | Buy |
9,726
+5,701
| +142% | +$169K | ﹤0.01% | 5015 |
|
|
2018
Q3 | $166K | Sell |
4,025
-6
| -0.1% | -$338 | ﹤0.01% | 5095 |
|
|
2018
Q2 | $231K | Buy |
+4,031
| New | +$194K | ﹤0.01% | 4953 |
|
Other funds holding COGT
DM
VPM
VCM
FFM
RI
TCM
Wells Fargo's COGT Position: Q1 2026 in Review
Wells Fargo reduced its Cogent Biosciences (COGT) stake by 31% in Q1 2026, selling an estimated $1.73M and leaving 106,660 shares worth $4.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2761.
Wells Fargo first reported a position in COGT in Q2 2018 and has held it in 29 quarters since. The position peaked at $5.46M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.
- Wells Fargo held 106,660 shares of Cogent Biosciences worth $4.11M as of Q1 2026.
- Wells Fargo sold 46,965 Cogent Biosciences shares in Q1 2026, an estimated $1.73M.
- Cogent Biosciences made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #2761 holding.
- Wells Fargo first reported a position in Cogent Biosciences in Q2 2018 and has held it in 29 quarters since.
- Wells Fargo's Cogent Biosciences position peaked at $5.46M in Q4 2025.
- 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.